Home / Market News / $PPCB
fiscal.ai Corporate Catalyst Impact 95/100 ● negative

Propanc Biopharma Receives Nasdaq Delisting Notice

Oct 29, 2026, 10:12 PM UTC · Primary ticker $PPCB

Propanc Biopharma received a delisting notice from Nasdaq due to failing to meet the $1.00 minimum bid price requirement. The company is ineligible for a standard compliance period due to a recent reverse stock split, making this an immediate and severe threat to its public listing. This event is highly negative for current shareholders and could lead to significant liquidity issues if the appeal is unsuccessful.

Propanc Biopharma (PPCB) has received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement. This is a critical event because the company is not eligible for the usual compliance period due to a recent reverse stock split, meaning delisting is imminent unless a successful appeal is made. This directly impacts current shareholders who face the prospect of their shares being traded on over-the-counter markets, which typically have lower liquidity and transparency. In the short term, the stock is likely to experience significant downward pressure as investors react to the delisting threat. Long-term implications depend entirely on the outcome of the appeal; failure to reverse the decision could severely impair the company's ability to raise capital and maintain investor confidence. The key risk for traders is the potential for a rapid and substantial decline in share price if the appeal is denied, making it a highly speculative play even with the stated intention to appeal.

$PPCB negative Delisting notice from Nasdaq
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.